{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:34:40Z","timestamp":1761896080209},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:00:00Z","timestamp":1438214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s10067-015-3030-y","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T23:18:16Z","timestamp":1438125496000},"page":"801-805","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases"],"prefix":"10.1007","volume":"35","author":[{"given":"Flavio","family":"Signorelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius","family":"Domingues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique Ataide","family":"Mariz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,30]]},"reference":[{"key":"3030_CR1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295\u2013306","journal-title":"J Thromb Haemost"},{"key":"3030_CR2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-9560-11-18","volume":"11","author":"F Tahir","year":"2013","unstructured":"Tahir F, Riaz H, Riaz T, Badshah MB, Riaz IB, Hamza A, Mohiuddin H (2013) The new oral anti-coagulants and the phase 3 clinical trials \u2013 a systematic review of the literature. Thromb J 11:18","journal-title":"Thromb J"},{"key":"3030_CR3","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1177\/0961203314536480","volume":"23","author":"RA Levy","year":"2014","unstructured":"Levy RA, Signorelli FV (2014) Patient-health care provider relationship: how can it impact on APS (Hughes\u2019 syndrome) adherence to treatment? Lupus 23:1265\u20131268","journal-title":"Lupus"},{"key":"3030_CR4","doi-asserted-by":"crossref","unstructured":"Cohen H, Dor\u00e9 CJ, Clawson S, et al. (2015) Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphosphlipid syndrome, with or without SLE. Lupus; Published online before print May 4, 2015. doi: 10.1177\/0961203315581207","DOI":"10.1177\/0961203315581207"},{"key":"3030_CR5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.autrev.2015.03.007","volume":"14","author":"N Noel","year":"2015","unstructured":"Noel N, Dutasta F, Costedoat-Chalumeau N, Bienvenu B, Mariette X, Geffray L, Sene D, Chaidi RB, Michot JM, Fain O, Darnige L, Ankri A, Cacoub P, Piette JC, Saadoun D (2015) Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev 14:680\u2013685","journal-title":"Autoimmun Rev"},{"key":"3030_CR6","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.23109","volume":"57","author":"G Ruiz-Irastorza","year":"2007","unstructured":"Ruiz-Irastorza G, Hunt BJ, Khamashta MA (2007) A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 57:1487\u20131495","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3030_CR7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1590\/S0482-50042013000200005","volume":"53","author":"A Danowski","year":"2013","unstructured":"Danowski A, Rego J, Kakehasi AM et al (2013) Diretrizes para o tratamento da s\u00edndrome do anticorpo antifosfolip\u00eddeo. Rev Bras Reumatol 53(2):184\u2013192","journal-title":"Rev Bras Reumatol"},{"issue":"4","key":"3030_CR8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MBC.0000000000000247","volume":"26","author":"S Savino","year":"2015","unstructured":"Savino S, Breen K, Hunt BJ (2015) Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis 26(4):476\u20137","journal-title":"Blood Coagul Fibrinolysis"},{"key":"3030_CR9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1160\/TH14-03-0272","volume":"112","author":"JK Schaefer","year":"2014","unstructured":"Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE (2014) Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 112:947\u201350","journal-title":"Thromb Haemost"},{"key":"3030_CR10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.23797","volume":"89","author":"K Win","year":"2011","unstructured":"Win K, Rodgers GM (2011) New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 89:1017","journal-title":"Am J Hematol"},{"issue":"5","key":"3030_CR11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.thromres.2015.01.028","volume":"135","author":"M Son","year":"2015","unstructured":"Son M, Wypasek E, Lowenhoff-Celinska M, Undas A (2015) The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res 135(5):1035\u20136","journal-title":"Thromb Res"},{"key":"3030_CR12","unstructured":"Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS) Trial. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02157272 Accessed May 13, 2015"},{"key":"3030_CR13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","volume":"332","author":"MA Khamashta","year":"1995","unstructured":"Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993\u2013997","journal-title":"N Engl J Med"},{"issue":"1","key":"3030_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20\u20138","journal-title":"Ann Rheum Dis"},{"key":"3030_CR15","first-page":"105","volume":"2011","author":"E Merriman","year":"2011","unstructured":"Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H (2011) Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 2011:105","journal-title":"Thromb Haemost"},{"issue":"4","key":"3030_CR16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MBC.0000000000000235","volume":"26","author":"T G\u00f3ralczyk","year":"2015","unstructured":"G\u00f3ralczyk T, Iwaniec T, Wypasek E, Undas A (2015) False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul Fibrinolysis 26(4):473\u20135","journal-title":"Blood Coagul Fibrinolysis"},{"key":"3030_CR17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11926-013-0331-5","volume":"15","author":"DJ Arachchillage","year":"2013","unstructured":"Arachchillage DJ, Cohen H (2013) Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 15:331","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"3030_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-015-0568-7","volume":"17","author":"B Artim-Esen","year":"2015","unstructured":"Artim-Esen B, Pericleous C, Mackie I, Ripoll VM, Latchman D, Isenberg D, Rahman A, Ioannou Y, Giles I (2015) Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Res Ther 17(1):47","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-3030-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-015-3030-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-3030-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:57:42Z","timestamp":1559120262000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-015-3030-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["3030"],"URL":"https:\/\/doi.org\/10.1007\/s10067-015-3030-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,30]]}}}